Literature DB >> 7729516

Effects of TGF-beta 1 (transforming growth factor-beta 1) on the cell cycle regulation of human breast adenocarcinoma (MCF-7) cells.

P Mazars1, N Barboule, V Baldin, S Vidal, B Ducommun, A Valette.   

Abstract

The antiproliferative effects of TGF-beta 1 were investigated in a human breast adenocarcinoma cell line (MCF-7). We report that TGF-beta 1 inhibits proliferation through cell cycle arrest in G1. A MCF-7 cell subline (MCF-7(-)), in which the type II TGF-beta receptor is not detected, was shown to be resistant to TGF-beta 1 growth inhibitory effect. Cdk2 kinase activity was inhibited in the MCF-7 sensitive cell subline in parallel with the inhibition of cell cycle progression. In both sensitive and resistant cell lines, TGF-beta 1 treatment did not affect cdk2, cdk4, cyclin E and cyclin D1 mRNA and protein levels. However, in the MCF-7 sensitive cell subline, a time-dependent increase in cells positive for p21WAF1/CIP1 nuclear localization was observed after TGF-beta 1 treatment. These findings suggest that TGF-beta 1 inhibition of MCF-7 cell proliferation is achieved through a type II receptor-dependent down-regulation of Cdk2 kinase activity without modification of Cdk and cyclin expression, but correlated with an increase in p21WAF1/CIP1 nuclear accumulation.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7729516     DOI: 10.1016/0014-5793(95)00247-7

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  10 in total

1.  Responsiveness to transforming growth factor-beta (TGF-beta)-mediated growth inhibition is a function of membrane-bound TGF-beta type II receptor in human breast cancer cells.

Authors:  M A Lynch; T A Petrel; H Song; T J Knobloch; B C Casto; D Ramljak; L M Anderson; V DeGroff; G D Stoner; R W Brueggemeier; C M Weghorst
Journal:  Gene Expr       Date:  2001

2.  Evidence for control of nitric oxide synthesis by intracellular transforming growth factor-beta1 in tumor cells. Implications for tumor development.

Authors:  P Lagadec; S Raynal; B Lieubeau; N Onier; L Arnould; V Saint-Giorgio; D A Lawrence; J F Jeannin
Journal:  Am J Pathol       Date:  1999-06       Impact factor: 4.307

3.  Positive and negative regulation of type II TGF-beta receptor signal transduction by autophosphorylation on multiple serine residues.

Authors:  K Luo; H F Lodish
Journal:  EMBO J       Date:  1997-04-15       Impact factor: 11.598

4.  BRCA1 regulates transforming growth factor-β (TGF-β1) signaling through Gadd45a by enhancing the protein stability of Smad4.

Authors:  Dan Li; Nan Kang; Junfang Ji; Qimin Zhan
Journal:  Mol Oncol       Date:  2015-05-14       Impact factor: 6.603

5.  Neutral sphingomyelinase-2 mediates growth arrest by retinoic acid through modulation of ribosomal S6 kinase.

Authors:  Christopher J Clarke; Krutika Mediwala; Russell W Jenkins; Che A Sutton; Baby G Tholanikunnel; Yusuf A Hannun
Journal:  J Biol Chem       Date:  2011-05-02       Impact factor: 5.157

Review 6.  Defects of TGF-beta receptor signaling in mammary cell tumorigenesis.

Authors:  M G Brattain; Y Ko; S S Banerji; G Wu; J K Willson
Journal:  J Mammary Gland Biol Neoplasia       Date:  1996-10       Impact factor: 2.673

Review 7.  Complex role of tumor cell transforming growth factor (TGF)-beta s on breast carcinoma progression.

Authors:  K M Koli; C L Arteaga
Journal:  J Mammary Gland Biol Neoplasia       Date:  1996-10       Impact factor: 2.673

8.  Differential regulation of human thymosin beta 15 isoforms by transforming growth factor beta 1.

Authors:  Jacqueline Banyard; Courtney Barrows; Bruce R Zetter
Journal:  Genes Chromosomes Cancer       Date:  2009-06       Impact factor: 5.006

9.  Rapamycin enhances the antiproliferative effect of transforming growth factor-β on MCF-7 human breast cancer cells.

Authors:  Guoping Wang; Tao Yin
Journal:  Exp Ther Med       Date:  2017-06-07       Impact factor: 2.447

10.  Breast cancer anti-estrogen resistance 3 inhibits transforming growth factor β/Smad signaling and associates with favorable breast cancer disease outcomes.

Authors:  Jimin Guo; Lucie Canaff; Charles Vincent Rajadurai; Nadège Fils-Aimé; Jun Tian; Meiou Dai; Juliana Korah; Manuel Villatoro; Morag Park; Suhad Ali; Jean-Jacques Lebrun
Journal:  Breast Cancer Res       Date:  2014-12-13       Impact factor: 6.466

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.